Clinical Trials · NCT01840449

Somatuline Predictive Factors in Acromegaly and NET

Name: Somatuline Predictive Factors in Acromegaly and NET
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ALanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 156
Start date: Jun 2012
Locations: 3 sites, 3 countries
Primary endpoint: Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)

View Lanreotide compound reference